- Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia. 2011; 7(3):257-62.
- Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018; 14(4):535-62.
- Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, Maruff P, Miller DS, Tong G, Tome MB, Murray ME. The National Institute on Aging and the Alzheimer's Association research framework for Alzheimer's disease: perspectives from the research roundtable. Alzheimer's & Dementia. 2018; 14(4):563-75.
- Devous MD, Sr., Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, et al. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. J Alzheimers Dis. 2021; 80:1091-104.
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers 2011; 7:263-9.
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:270-9.
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003; 46:2740-54.
- Hosokawa C, Ishii K, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, et al. Investigation of (11)C-PiB equivocal PET findings. Ann Nucl Med. 2015; 29:164-9.
- Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med. 2016; 57:208-14.
- Hirayama A, Yamada T, Ishii K. Comparison with regional glucose metabolism, amyloid deposition and tau deposition between dementia with Lewy bodies and Alzheimer disease brains. Acta Medica Kindai University. 2022; 47: 11-16.
- Ishii K, Yamada T, Hanaoka K, Kaida H, Miyazaki K, Ueda M, et al. Regional gray matter-dedicated SUVR with 3D-MRI detects positive amyloid deposits in equivocal amyloid PET images. Ann Nucl Med. 2020; 34:856-63.
- Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016; 61:5768-80.
- Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuro-psychological correlates. J Neurol Neurosurg Psychiatry. 1992; 55:967-72.
- Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's Alzheimers Dement. 2011; 7:280-92.
- Thientunyakit T, Thongpraparn T, Sethanandha C, Yamada T, Kimura Y, Muangpaisan W, et al. Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. Jpn J Radiol. 2021; 39:984-93.
- Qiao Z, Wang G, Zhao X, Wang K, Fan D, Chen Q, et al. Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. Front Aging Neurosci. 2022; 14:841942.
- Nobili F, Mazzei D, Dessi B, Morbelli S, Brugnolo A, Barbieri P, et al. Unawareness of memory deficit in amnestic MCI: FDG-PET findings. J Alzheimers Dis. 2010; 22:993-1003.
- Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of (18)F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. J Nucl Med. 2018; 59:671-4.
- Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte Biomarkers in Alzheimer's disease. Trends Mol Med. 2019; 25:77-95.
- Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol. 2014; 35:2030-8.
- Matsuda H, Shigemoto Y, Sato N. Neuro imaging of Alzheimer's disease: focus on amyloid and tau PET. Jpn J Radiol. 2019; 37:735-49.
- Sintini I, Schwarz CG, Martin PR, Graff-Radford J, Machulda MM, Senjem ML, et al. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Hum Brain Mapp. 2019; 40:1618-31.
|